Dramatic Drug Cost Hikes To Be Subject Of Wednesday Senate Hearing
Meanwhile, The New York Times takes a look at Martin Shkreli, the pharmaceutical company official who has become the poster boy of drug company greed.
The Wall Street Journal:
Rising Drug Costs To Be In Focus At Congressional Hearing
Dramatic price increases for several medicines are scheduled to be the subject of a congressional hearing in the coming week. Companies including Valeant Pharmaceuticals International Inc. and Turing Pharmaceuticals AG have been under fire this year from doctors, patients and lawmakers over rising drug costs. Such increases have prompted investigations by congressional committees, and House Democrats have established a task force to probe drug pricing. On Wednesday, the Senate Special Committee on Aging is scheduled to hold a hearing further exploring the matter. (Rockoff, 12/5)
The New York Times:
Martin Shkreli, The Bad Boy Of Pharmaceuticals, Hits Back
A former hedge fund manager, Mr. Shkreli drew the wrath of consumers, became a talking point in the presidential campaign, and spurred federal and state inquiries as well as a dialogue about how and whether to control rising drug prices. As proof of Mr. Shkreli’s toxicity, Bernie Sanders rejected his $2,700 campaign donation, turning it over to a health clinic instead. ... Mr. Shkreli’s price increase is likely to take another pummeling at a Senate committee hearing investigating skyrocketing drug prices next Wednesday. Rather than cower as he takes a beating, Mr. Shkreli seems to relish his time in the ring. (Creswell and Pollack, 12/5)